reports
Starker Verkaufsstart von Cresemba in Japan löst erste Umsatzmeilenste...
Starker Verkaufsstart von Cresemba in Japan löst erste Umsatzmeilensteinzahlung von AKP an Basilea aus Allschwil, 05. Februar 2025 Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zu helfen, die an schweren Infektionen durch Bakterien oder Pilze erkrankt sind, berichtete heute, dass die Verkäufe des Antimykotikums Cresemba® (Isavuconazol) in Japan die Schwelle überschritten haben, durch welche die erste Umsatzmeilensteinzahlung von seinem Partner Asahi Kasei Pharma (AKP) in Höhe von rund CHF 1.2 ...
Strong launch for Cresemba in Japan triggers first sales milestone pay...
Strong launch for Cresemba in Japan triggers first sales milestone payment from AKP to Basilea Allschwil, Switzerland, February 05, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, reported today that the sales of the antifungal Cresemba® (isavuconazole) in Japan exceeded the threshold triggering the first sales milestone payment from its partner Asahi Kasei Pharma (AKP), amounting to approximately CHF 1.2 million. David Veitch, Chief ...
Starkes Verkaufswachstum von Cresemba und Zevtera löst weitere Meilens...
Starkes Verkaufswachstum von Cresemba und Zevtera löst weitere Meilensteinzahlungen an Basilea aus Allschwil, 28. Januar 2025 Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zu helfen, die an schweren Infektionen durch Bakterien oder Pilze erkrankt sind, berichtete heute, dass die Verkäufe des Antimykotikums Cresemba® (Isavuconazol) und des Antibiotikums Zevtera® (Ceftobiprol) im Jahr 2024 Schwellen überschritten haben, durch die Umsatzmeilensteinzahlungen von Distributionspartnern in einer Höhe...
Strong sales growth for Cresemba and Zevtera trigger further milestone...
Strong sales growth for Cresemba and Zevtera trigger further milestone payments to Basilea Allschwil, Switzerland, January 28, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, reported today that the sales in 2024 of the antifungal Cresemba® (isavuconazole) and the antibiotic Zevtera® (ceftobiprole) exceeded thresholds triggering sales milestone payments from distribution partners to Basilea, in the total amount of approximately CHF 2.2 million. For...
Basilea informiert über Stand seines Portfolios und gibt Ausblick
Basilea informiert über Stand seines Portfolios und gibt Ausblick Allschwil, 08. Januar 2025 Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zu helfen, die an schweren Infektionen durch Bakterien oder Pilze erkrankt sind, berichtete heute über die in 2024 erzielten Fortschritte im Forschungs- und Entwicklungsportfolio und bevorstehende Meilensteine. David Veitch, Chief Executive Officer von Basilea, sagte: «Im Jahr 2024 haben wir eine Reihe von wichtigen Meilensteinen erreicht. Für unser Anti-M...
Basilea provides portfolio update and outlook
Basilea provides portfolio update and outlook Allschwil, Switzerland, January 08, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, reported today on the progress of its Research & Development portfolio in 2024 and upcoming milestones. David Veitch, Chief Executive Officer, said: “We have achieved several significant milestones in 2024. We partnered with a highly committed, focused and capable company for the commercialization of our anti-MRSA antibio...
Basilea erhält zusätzliche CARB-X-Förderung für die Entwicklung eines ...
Basilea erhält zusätzliche CARB-X-Förderung für die Entwicklung eines Medikamentenkandidaten einer neuen Antibiotika-Wirkstoffklasse Zusätzliche finanzielle Förderung aufgrund erfolgreicher Nominierung eines WirkstoffkandidatenUSD 7.3 Mio. zur Unterstützung der Entwicklung des Antibiotikums BAL2420 (LptA-Inhibitor) hin zu ersten klinischen Studien am Menschen Ad hoc-Mitteilung gemäss Art. 53 KR Allschwil, 23. Dezember 2024 Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten...
Basilea is awarded additional CARB-X funding to develop new drug candi...
Basilea is awarded additional CARB-X funding to develop new drug candidate from a novel class of antibiotics Additional funding awarded following successful drug candidate nominationUSD 7.3 million to support progression of antibiotic BAL2420 (LptA inhibitor) towards first-in-human clinical studies Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, December 23, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it wa...
- Sean Conroy
Basilea Pharmaceutica - Partner in place for US commercialisation of Z...
Following FDA approval in April 2024, Basilea has announced a much-anticipated partnership agreement with Innoviva Specialty Therapeutics for the commercialisation of Zevtera in the US. Deal terms include an upfront payment of US$4m, as well as tiered royalties on net sales in the high-teens to mid-20s percentage range. In addition, the company is eligible to receive up to US$223m in sales-related milestone payments. We view this as an important milestone and highly favourable transaction for Ba...
- Bruno Bulic
Basilea out-licensing Zevtera to Innoviva
Basilea announced the out-licensing of the commercial rights to Zevtera for the US to Innoviva, disclosing USD4m upfront and tiered royalties on net sales in the high-teens to mid-twenties percentage range, as well as sales milestones of up to USD223m. As the company clearly previously indicated ma
Basilea gibt Vereinbarung mit Innoviva Specialty Therapeutics zur Verm...
Basilea gibt Vereinbarung mit Innoviva Specialty Therapeutics zur Vermarktung von Antibiotikum Zevtera® (Ceftobiprol) in den Vereinigten Staaten bekannt Ad hoc-Mitteilung gemäss Art. 53 KR Allschwil, 16. Dezember 2024 Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zu helfen, die an schweren Infektionen durch Bakterien oder Pilze erkrankt sind, gab heute bekannt, dass es mit Innoviva Specialty Therapeutics, Inc., einer vollständigen Tochtergesellschaft von Innoviva Inc. (NASDAQ: INVA), eine e...
Basilea announces agreement with Innoviva Specialty Therapeutics for t...
Basilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera® (ceftobiprole) in the United States Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, December 16, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has entered into an exclusive distribution and license agreement with Innoviva Specialty Therapeutics, Inc., a wholly owned subsidiary of Innoviv...
Basilea Pharmaceutica AG: 1 director
A director at Basilea Pharmaceutica AG sold 500 shares at 45.000CHF and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...
- Sean Conroy
Basilea Pharmaceutica - Milestone march continues for Cresemba
Basilea Pharmaceutica has reported another US$1.25m milestone payment from its partner Pfizer in Asia-Pacific and China, triggered by Cresemba sales in this region crossing a pre-defined threshold. This is the fourth milestone payment for Cresemba from the region this year, adding to the already strong H2 results (c CHF33m/US$38.5m milestone payments recorded in H224 so far; CHF35m in 2024 to date). The Asia-Pacific region, particularly China (which accounts for c 20% of the market potential for...
Starke Cresemba® (Isavuconazol)-Umsätze in Asien-Pazifik und China lös...
Starke Cresemba® (Isavuconazol)-Umsätze in Asien-Pazifik und China lösen vierte Meilensteinzahlung für diese Region in diesem Jahr an Basilea aus Allschwil, 10. Oktober 2024 Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zu helfen, die an schweren Infektionen durch Bakterien oder Pilze erkrankt sind, gab heute bekannt, dass die anhaltend guten Verkäufe des Antimykotikums Cresemba® (Isavuconazol) durch Basileas Lizenzpartner Pfizer Inc. in der Region Asien-Pazifik und China die Schwelle überschr...
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and...
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers fourth milestone payment for this region to Basilea this year Allschwil, Switzerland, October 10, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the continued strong sales performance of the antifungal Cresemba® (isavuconazole) by its license partner Pfizer Inc. in the Asia Pacific region and China exceeded the sales threshold triggering a USD ...
- Sean Conroy
Basilea Pharmaceutica - BARDA backs Basilea’s anti-infectives programm...
Basilea has bagged a multi-year agreement with the Biomedical Advanced Research and Development Authority (BARDA), potentially worth US$268m, to advance its anti-infectives franchise. The Other Transaction Agreement (OTA) will include an initial payment of US$29m to support clinical development work for fosmanogepix and BAL2062 as they prepare to enter the next phase of clinical development. The agreement will last up to 12 years and management expects it to cover 60% of its development costs re...
Basilea initiiert klinische Phase-3-Studie mit Antipilzmittel Fosmanog...
Basilea initiiert klinische Phase-3-Studie mit Antipilzmittel Fosmanogepix bei Candidämie und invasiver Candidiasis Allschwil, 24. September 2024 Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zu helfen, die an schweren Infektionen durch Bakterien oder Pilze erkrankt sind, gab heute bekannt, dass es die Phase-3-Studie FAST-IC (Fosmanogepix Against Standard-of-care Treatment in Invasive Candidiasis) initiiert hat. In dieser zulassungsrelevanten Studie wird die Wirksamkeit und Sicherheit von Basi...
Basilea initiates clinical phase 3 study with antifungal fosmanogepix ...
Basilea initiates clinical phase 3 study with antifungal fosmanogepix in candidemia and invasive candidiasis Allschwil, Switzerland, September 24, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has initiated the Fosmanogepix Against Standard-of-care Treatment in Invasive Candidiasis (FAST-IC) phase 3 study. This registrational study evaluates the efficacy and safety of Basilea’s broad-spectrum antifungal fosmanogepix in the tre...
- Bruno Bulic
- Oscar Haffen Lamm
Basilea pipeline validated by US BARDA, guidance upgraded
Basilea today lifted FY24 guidance, raising net profit by whopping 43% (CHF 60m versus previous CHF 42m) and revenue by 3.6% following the decision of the US BARDA agency to support Basilea pipeline development with an initial USD 29m funding, of which Basilea intends to recognize CHF 7m in H2 24.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.